Introduction {#s1}
============

Colorectal cancer (CRC) is considered the third most commonly diagnosed cancer in males and the second in females worldwide, with an estimated 1.8 million new cases in 2018. In the same year, CRC was responsible for 881 000 deaths, making it the second leading cause of cancer-related death in men and women.[@R1] The largest proportion of CRC occurs in the rectum and sigmoid colon, while a smaller proportion occurs in caecum and ascending colon. About 20% of patients have synchronous metastases at diagnosis, frequently in the liver, and about 35% of patients develop metastases after a curative intent treatment.[@R2] In the past decade, the increasing number of effective drugs, the improvement of surgical procedures and the availability of different local ablative treatment (LAT), led to a significant increase in overall survival (OS) of metastatic CRC (mCRC) patients which is now ∼30 months.

Diagnosis, staging and treatment planning {#s2}
=========================================

After histological diagnosis of CRC, physical examination, blood count, and renal and liver function can help to define the clinical status of the patient. Thoracoabdominal CT scan is the best option to identify distant metastases, while MRI is more sensitive to detect malignant liver lesions. PET scan is useful only in case of lesions of uncertain significance.[@R3]

In order to optimise treatment strategy, the institution of a multidisciplinary team (MDT) is crucial to determine the goal to achieve. In fact, treatment algorithm has been tailored according to three major points: (1) patient characteristics (performance status (PS), comorbidities, age and previous adjuvant treatment) and preferences (quality of life (QoL), acceptance of toxicities and expectations); (2) tumour features (tumour burden, pattern of progression, sites of metastasis, potential resectable metastases and primary tumour location); (3) molecular profile (*RAS/BRAF* status, microsatellite instability (MSI), and---eventually---human epidermal growth factor receptor (HER2 overexpression and *NTRK* (neurotrophic tyrosine receptor kinase) rearrangement) ([figure 1](#F1){ref-type="fig"}).

![Algorithm for the treatment of mCRC. Bev, bevacizumab; *BRAF*, v-raf murine sarcoma viral oncogene homolog B1; EGFR, epidermal growth factor receptor; FP, fluoropyrimidine; HER2, human epidermal growth factor receptor 2; mCRC, metastatic colorectal cancer; MDT, multidisciplinary team; MSI, microsatellite instability; *NTRK,* neurotrophic tyrosine receptor kinase; *RAS*, rat sarcoma viral oncogene homolog; wt, wild-type.](esmoopen-2020-000813f01){#F1}

First-line treatment {#s3}
====================

Effective first-line therapy is a key determinant of successful treatment in mCRC ([table 1A](#T1){ref-type="table"}). Many different factors influence the choice of upfront treatment, including patient characteristics, tumour features and molecular profile. Indeed, it is important to evaluate the comorbidities and age of the patient that can affect the possibility of using a more intensive approach: in particular, patients will be assessed as fit or unfit according to medical condition not due to malignant disease. In the case of unfit patients, physician experience should drive treatment decision with potential treatment options: capecitabine+bevacizumab or a dose-adjusted doublet chemotherapy.[@R4] In the case of unfit *RAS* wild-type (WT) patients, if there is the possibility that they may be receiving further treatments, anti-EGFR therapy can be considered.

###### 

Main clinical trials in (A) first-line, (B) second-line and (C) further lines for mCRC

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical trial                               Population                                                                                                        Treatment                 mOS                                    mPFS                                           ORR                   
  -------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------- ------------------ ------------------- ------------------------- -------------------- --------------------- -------------------
  **(A) First-line chemotherapy treatment**                                                                                                                                                                                                                                                            

  Hurwitz,\                                    Unselected mCRC                                                                                                   IFL+bev\                  20.3 m\            HR 0.66\            10.6 m\                   HR 0.54\             44.8%\                p=0.004
  NEJM 2004                                                                                                                                                      IFL+placebo               15.6 m             p\<0.001            6.2 m                     p\<0.001             34.8%                 

  Saltz,\                                      Unselected mCRC                                                                                                   XELOX/FOLFOX+bev\         21.3 m\            HR 0.89\            9.4 m\                    HR 0.83\             47%\                  p=0.31
  JCO 2008                                                                                                                                                       XELOX/FOLFOX+placebo      19.9 m             p=0.077             8.0 m                     p=0.0023             49%                   

  OPUS trial\                                  Unselected mCRC (analysis for *KRAS* exon 2 wt subgroup in brackets)                                              FOLFOX+cet\               22.8 m (19.8 m)\   HR 0.86 (0.94)\     8.3 m (12.0 m)\           HR 0.57 (0.53)\      57% (58%)\            p=0.0027 (0.0084)
  Bokmeyer,\                                                                                                                                                     FOLFOX                    18.5 m (17.8 m)    p=0.39 (0.80)       7.2 m (5.8 m)             p=0.0064 (0.0615)    34% (29%)             
  JCO 2009\                                                                                                                                                                                                                                                                                            
  (update Ann Onc 2015)                                                                                                                                                                                                                                                                                

  CRYSTAL trial\                               Unselected mCRC (analysis for *KRAS* exon 2 wt subgroup in brackets)                                              FOLFIRI+cet\              23.5 m (28.4 m)\   HR 0.80 (0.69)\     9.9 m (11.4 m)\           HR 0.70 (0.56)\      57.3% (66.3)\         p\<0.001\
  Van Cutsem,\                                                                                                                                                   FOLFIRI                   20.0 m (20.2 m)    p=0.0093 (0.0024)   8.4 m (8.4 m)             p=0.0012 (\<0.001)   39.7% (38.6)          (\<0.001)
  NEJM2009, update JCO 2015                                                                                                                                                                                                                                                                            

  PRIME trial\                                 Unselected mCRC, analysis only for *KRAS* exon 2 wt subgroup                                                      FOLFOX+pan\               23.9 m\            HR 0.83\            9.6 m\                    HR 0.80\             55%\                  p=0.068
  Douillard,\                                                                                                                                                    FOLFOX                    19.7 m             p=0.072             8.0 m                     p=0.02               48%                   
  JCO 2010                                                                                                                                                                                                                                                                                             

  Kohne,\                                      Unselected mCRC, single-arm trial (analysis for *KRAS* exon 2 wt versus mut subgroups in brackets)                FOLFIRI+pan               /                  /                   7.6 m (8.9 m in RASwt,\   HR 0.5               49% (56% in RASwt,\    
  J Cancer Res Clin Oncol 2012                                                                                                                                                                                                    7.2 m in RASmut)                               39% in RASmut)        

  FIRE-3 trial\                                *KRAS* exon 2 wt mCRC (analysis for *KRAS*/*NRAS* exons 2 to 4 wt subgroup in brackets)                           FOLFIRI+cet\              28.7 m (33.1 m)\   HR 0.77 (0.70)\     10.0 m (10.3 m)\          HR 1.06 (0.97)\      62% (65.3)\           p=0.18 (0.18)
  Stintzing,\                                                                                                                                                    FOLFIRI+bev               25.0 m (25.0 m)    p=0.017 (0.0059)    10.3 m (10.2 m)           p=0.55 (0.77)        58% (58.7)            
  Lancet 2016                                                                                                                                                                                                                                                                                          

  CALGB/SWOG 80405 trial\                      *KRAS* exon 2 wt mCRC (extended *RAS* wt subgroup in brackets)                                                    FOLFOX/FOLFIRI+cet\       30.0 m (31.5 m)\   HR 0.88 (0.91)\     10.5 m (10.9)\            HR 0.95 (0.90)\      59.6%\                p=0.13
  Venook,\                                                                                                                                                       FOLFOX/FOLFIRI+bev        29.0 m (33.3 m)    p=0.08 (0.459)      10.6 m (11.1 m)           p=0.45 (0.359)       55.2%                 
  JAMA 2017                                                                                                                                                                                                                                                                                            

  PEAK trial\                                  *KRAS* exon 2 wt mCRC (extended *RAS* wt subgroup in brackets)                                                    FOLFOX+pan\               34.2 m (41.3 m)\   HR 0.62 (0.63)\     10.9 m (13.0 m)\          HR 0.87 (0.65)\      57.8% (63.6)\         /
  Schwartzberg,\                                                                                                                                                 FOLFOX+bev                24.3 m (28.9 m)    p=0.009 (0.058)     10.1 m (9.5 m)            p=0.353 (0.029)      53.5% (60.5)          
  JCO 2014                                                                                                                                                                                                                                                                                             

  TRIBE trial\                                 Unselected mCRC                                                                                                   FOLFOXIRI+bev\            29.8 m\            HR 0.80\            12.3 m\                   HR 0.77\             65%\                  p=0.013
  Loupakis, Cremolini,\                                                                                                                                          FOLFIRI+bev               25.8 m             p=0.03              9.7 m                     p=0.006              54%                   
  NEJM 2014, Lancet 2015[@R9]                                                                                                                                                                                                                                                                          

  **(B) Second-line chemotherapy treatment**                                                                                                                                                                                                                                                           

  ECOG E3200 trial\                            mCRC previously treated with a fluoropyrimidine and irinotecan                                                    FOLFOX+bev\               12.9 m\            HR 0.75\            7.3 m\                    HR 0.61\             22.7%\                p\<0.0001
  Giantonio,\                                                                                                                                                    FOLFOX                    10.8 m             p=0.0011            4.7 m                     p\<0.0001            8.6%                  
  JCO 2007[@R18]                                                                                                                                                                                                                                                                                       

  Cao,\                                        mCRC previously treated with oxaliplatin-based CT                                                                 FOLFIRI+bev\              15.2 m\            /                   8.5 m\                    /                    47.7%\                p=0.001
  Med Oncol 2015[@R20]                                                                                                                                           FOLFIRI                   11.3 m                                 5.1 m                                          28.5%                 

  ML18147 trial\                               mCRC previously treated with CT+bev                                                                               CT+bev\                   11.2 m\            HR 0.83\            5.7 m\                    HR 0.68\             5%\                   /
  Bennouna,\                                                                                                                                                     CT                        9.8 m              p=0.0211            4.1 m                     p\<0.0001            4%                    
  Lancet Oncol 2013[@R21]                                                                                                                                                                                                                                                                              

  BEBYP trial\                                 mCRC previously treated with CT+bev                                                                               CT+bev\                   14.1 m\            HR 0.77\            6.8 m\                    HR 0.70\             21%\                  p=0.573
  Masi,\                                                                                                                                                         CT                        15.5 m             p=0.043             5.0 m                     p=0.010              17%                   
  Ann Oncol 2015[@R19]                                                                                                                                                                                                                                                                                 

  VELOUR trial\                                mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab                       FOLFIRI+aflib\            13.5 m\            HR 0.817\           6.9 m\                    HR 0.758\            19.8%\                p\<0.001
  Van Cutsem,\                                                                                                                                                   FOLFIRI                   12.06 m            p=0.0032            4.67 m                    p\<0.0001            11.1%                 
  JCO 2012[@R22]                                                                                                                                                                                                                                                                                       

  EPIC trial\                                  Unselected mCRC previously treated with oxaliplatin and fluoropyrimidine                                          Irinotecan+cet\           10.7 m\            HR 0.975\           4.0 m\                    HR 0.692\            16.4%\                p\<0.0001
  Sobrero\                                                                                                                                                       Irinotecan                10.0 m             p=0.71              2.6 m                     p≤0.0001             4.2%                  
  JCO 2008[@R24]                                                                                                                                                                                                                                                                                       

  Peeters\                                     Unselected mCRC previously treated without irinotecan or anti-EGFR. Analysis only for *KRAS* exon 2 wt subgroup   FOLFIRI+pan\              14.5 m\            HR 0.85\            5.9 m\                    HR 0.73\             35%\                  p\<0.001
  JCO 2010[@R25]                                                                                                                                                 FOLFIRI                   12.5 m             p=0.12              3.9 m                     p=0.004              10%                   

  RAISE trial\                                 mCRC previously treated with oxaliplatin-based CT+bev                                                             FOLFIRI+ram\              13.3 m\            HR 0.844\           5.7 m\                    HR 0.793\            13.4%\                p=0.63
  Tabernero,\                                                                                                                                                    FOLFIRI                   11.7 m             p=0.0219            4.5 m                     p\<0.0005            12.5%                 
  Lancet Oncol\                                                                                                                                                                                                                                                                                        
  2015[@R23]                                                                                                                                                                                                                                                                                           

  **(C) Further lines**                                                                                                                                                                                                                                                                                

  CORRECT trial\                               Unselected mCRC progressed after all standard therapies                                                           Regorafenib\              6.4 m\             HR 0.77\            1.9 m\                    HR 0.49\             1%\                   p=0.19
  Grothey,\                                                                                                                                                      Placebo                   5.0 m              p=0.0052            1.7 m                     p\<0.0001            0.4%                  
  Lancet 2013[@R26]                                                                                                                                                                                                                                                                                    

  RECOURSE trial\                              Unselected mCRC progressed after all standard therapies                                                           Trifluridine/tipiracil\   7.1 m\             HR 0.68\            2.0 m\                    HR 0.48\             1.6%\                 p=0.29
  Mayer,\                                                                                                                                                        Placebo                   5.3 m              p\<0.001            1.7 m                     p\<0.001             0.4%                  
  NEJM 2015                                                                                                                                                                                                                                                                                            

  CO.17 trial\                                 *KRAS* wt exon 2 mCRC progressed after all standard CT (w/o anti-EGFR)                                            Cetuximab\                9.5 m\             HR 0.55\            3.7 m\                    HR 0.40\             12.8%\                /
  Karapetis,\                                                                                                                                                    Placebo                   4.8 m              p\<0.001            1.9 m                     p\<0.001             1.2%                  
  NEJM 2008[@R33]                                                                                                                                                                                                                                                                                      

  Van Cutsem\                                  Unselected mCRC progressed after all standard CT                                                                  Panitumumab\              No difference      HR 1\               8.0 w\                    HR 0.54\             10%\                  p\<0.0001
  JCO 2007[@R34]                                                                                                                                                 Placebo                                      p=0.81              7.3 w                     p\<0.0001            0%                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

/, not reported; aflib, aflibercept; cet, cetuximab; FOLFIRI, irinotecan, leucovorin and 5-fluorouracil; FOLFOX, oxaliplatin, leucovorin, 5-fluorouracil; IFL, irinotecan, leucovorin, 5-fluorouracil; m, months; mCRC, metastatic colorectal cancer; mut, mutant; ORR, overall response rate; OS, overall survival; pan, panitumumab; PFS, progression-free survival; ram, ramucirumab; w, weeks; WT, wild type; XELOX, oxaliplatin and capecitabine.

In presence of fit patient, the best diagnostic and subsequent therapeutic decision-making available are managed by MDT: it should establish achievable goals and coordinate the different specialists to reach them through the four possible scenarios:

1.  **Clearly resectable metastases:** In patients with technically easily resectable disease (ensuring a surgical procedure with adequate safety margins) and favourable prognostic criteria, upfront resection is recommended. In those patients where the prognosis is unclear or unfavourable,[@R6] perioperative chemotherapy (overall 6 months with FOLFOX or CAPOX) is mandatory. No indication for the use of target agents in this setting is available.[@R7] Moreover, in patients who have not received any prior systemic chemotherapy, adjuvant treatments with FOLFOX or CAPOX is recommended.

2.  **Potentially curable with a conversion therapy:** In patients for whom the goal is tumour shrinkage or cytoreduction, intensive systemic treatment with the aim of conversion therapy is necessary. Before planning the treatment strategy, it is essential to consider molecular profile (*RAS* and *BRAF* status), tumour location (left versus right) and patient characteristic. For those patients who have left-sided *RAS* WT disease, cytotoxic doublet plus an anti-EGFR antibody should be treatment of choice.[@R8] For the ones with right-sided *RAS* WT disease, cytotoxic triplet+bevacizumab should be the treatment of choice, but cytotoxic doublet plus an anti-EGFR treatment can be another option for patients with any contraindication.[@R9] For those patients with *RAS* or *BRAF*-mutant disease, a cytotoxic doublet+bevacizumab or cytotoxic triplet+bevacizumab (in fit and suitable patients) are the preferred options.[@R10] After starting these 'conversion therapies', patients must be re-evaluated every 8 to 12 weeks with a maximum of 6 months to achieve the maximal response and to avoid overtreatment. Complete resection of the liver metastases is feasible, maintaining at least 30% of liver remnant; data of retrospective studies show a 5-year OS rates ranging from 25% to 58%.[@R11] Surgery R0 resection can be curative also with pulmonary metastasis, providing tumour-free margins.[@R12]

3.  **Oligometastatic disease:** It defines a subgroup of patients with better prognosis characterised by few sites of metastases (up to three different sites, with five or more lesions). The treatment strategy is based on the possibility of achieving complete ablation of all tumour masses using surgery R0 resection and/or LATs (thermal ablation techniques, conformal radiation techniques and embolisation techniques), either initially or possibly after induction treatment with systemic therapy.[@R13]

4.  **Never resectable disease:** In case of metastases not completely resectable with surgery, treatment goal is disease control rate and intensive protocols is not necessary. In this setting, a doublet chemotherapy plus a biologic agent is the standard of care, according to tumour molecular profile and 'sideness'. In particular, for those patients who have left-sided *RAS* WT disease, cytotoxic doublet plus an anti-EGFR antibody should be the treatment of choice. For the ones with right-sided *RAS* WT disease or *RAS* mutated, cytotoxic doublet+bevacizumab is the preferred option. The choice of a triplet chemotherapy is justified only with intent of cytoreduction in case of symptomatic disease, or in *BRAF*-mutant tumours due to their negative prognosis.[@R6]

After an induction therapy of 3 to 6 months, chiefly after an oxaliplatin-based chemotherapy, a maintenance treatment is possible to improve QoL. In particular, after FOLFOX/FOLFOXIRI+bevacizumab first-line therapy, maintenance with fluoropyrimidine+bevacizumab is preferred rather than bevacizumab alone.[@R14] Instead, subsequently a first-line with an anti-EGFR and a maintenance therapy with anti-EGFR+5-FU seems to be the best options but several trials are ongoing to address this question.[@R15]

Second-line treatment {#s4}
=====================

Second-line regimen choice depends on the systemic therapies given in first line. About two-thirds of mCRC patients received a second-line therapy. Typical second-line chemotherapy options include FOLFIRI or FOLFOX depending on the systemic therapy given in the first-line setting.[@R17] ([table 1B](#T1){ref-type="table"}) Furthermore, the addition of bevacizumab, in naïve-patients or 'beyond-progression', has demonstrated a benefit compared with chemotherapy alone.[@R18] Other two antiangiogenic drugs are available in second line in association with FOLFIRI: aflibercept, a fusion protein, improved OS in patients progressed to previously oxaliplatin-based chemotherapy even in those pretreated with bevacizumab;[@R22] ramucirumab, a monoclonal antibody against VEGFR2, also showed a gain in OS after a first line with FOLFOX+bevacizumab.[@R23] Cetuximab or panitumumab within an irinotecan-based therapy, can be both considered in second line in *RAS* WT tumours that haven't received any anti-EGFR, although the benefit is only in progression-free survival (PFS) and overall response rate (ORR) but not in OS.[@R24]

Further lines {#s5}
=============

In later lines, treatment goals must be QoL and PS maintenance, other than disease control. In this setting, regorafenib[@R26] (a multitargeted kinase inhibitor) and trifluridine/tipiracil[@R29] (an antimetabolite) have demonstrated similar OS benefit against placebo in chemorefractory mCRC patients ([table 1C](#T1){ref-type="table"}). In the absence of head-to-head comparative trials, choice of the sequence between the two drugs should be made according to patient's characteristics and comorbidity, considering the different toxicity profile.[@R30] In fact, trifluridine/tipiracil seems more manageable but with higher prevalence of neutropaenia. For regorafenib, dose is an issue and an escalating dose could permit a greater efficacy without affecting QoL, as described in several recent trials.[@R31] Furthermore, in *RAS* WT patients not previously treated with any anti-EGFR therapy, cetuximab or panitumumab have demonstrated similar survival benefit as third-line treatment.[@R33] Finally, re-challenge with previous drugs to which the tumour has already developed resistance, is an option in later lines, particularly if there was an adequate time interval. Few trials that addressed this topic with either oxaliplatin, irinotecan or anti-EGFR (in *RAS* WT tumours) did not demonstrate a clear benefit.[@R36] Therefore, differences in mechanisms of action and, more importantly, the safety profile of available third and further lines, including re-challenge treatments, may guide treatment selection for individual patients when QoL is the main goal.

Innovative strategies and new targets {#s6}
=====================================

Additional encouraging strategies have been studied in several subsets of patients in the past years. In particular, practice-changing results derived from BEACON trial. The trial has been conducted in patients with *BRAFV600E* mutation pretreated with at least one prior line of treatment. In this setting, the combination of encorafenib and cetuximab±binimetinib demonstrated a significant survival benefit compared with irinotecan+cetuximab or FOLFIRI+cetuximab: this led to the FDA (Food and Drug Administration) approval of encorafenib+cetuximab in *BRAFV600E*-mutant mCRC after prior therapy (European Medicines Agency approval is going to follow).[@R38] Open questions remain: (1) the addition of binimetinib has not improve OS compared with encorafenib+cetuximab alone; (2) this therapy could be effective also in first line (results of ANCHOR trial are expected in the next months).

Furthermore, although immunotherapy revolutionised the oncology landscape in the last 10 years, this success did not involve mCRC therapy. Different trials evaluating immunotherapy alone or in combination failed to demonstrate any efficacy in unselected population.[@R39] Nevertheless, in patients with deficient mismatch repair (dMMR)/MSI-H phenotype, which represents 4% to 5% of mCRC, results are very promising. Recently, pembrolizumab showed impressive results in this population in first line compared with standard chemotherapy in terms of median PFS (16.5 vs 8.2 months; HR 0.60; p=0.0002), ORR (43.8% vs 33.1%) and duration of response: this study will probably change the scenarios in this setting by becoming the new standard of care, making the assessment of MSI mandatory at diagnosis.[@R40] Furthermore, a recent update of the first-line CheckMate 142 trial, mCRC patients treated with 3 mg/kg nivolumab and 1 mg/kg ipilimumab showed an ORR of 69%, and a 24-month PFS and OS rates of 74% and 79%, respectively.[@R41] Previously, in MSI-H heavily pretreated patients, pembrolizumab and nivolumab have already demonstrated a good efficacy in terms of ORR and PFS.[@R42]

Finally, approximately 3% to 4% of mCRC patients harboured HER2 amplifications. HERACLES-A, a multicentre clinical trial, showed that a dual blockade of HER2 is effective in mCRC patients with amplification of this oncogene, providing ORR as high as 30% with the combination of trastuzumab and lapatinib.[@R44] Similar results have been obtained in this subgroup of patients with the combination of pertuzumab and trastuzumab (MyPathway phase II trial), that achieved a 32% ORR in heavily pretreated patients.[@R45] Recently, in the phase II DESTINY-CRC01 trial, trastuzumab deruxtecan, an antibody-drug conjugate, demonstrated remarkable activity in pretreated HER2-expressing mCRC, being careful of interstitial lung disease as critical toxicity.[@R46]

Ultimately, larotrectinib and entrectinib in tumours harbouring rearrangements of the *NTRK*1, *NTRK*2 or *NTRK*3 gene showed good efficacy in heavily pretreated mCRC.[@R47]

Conclusion {#s7}
==========

CRC is an heterogeneous entity for which therapeutic algorithm need to be chosen upfront by a multidisciplinary tumour board in order to ensure the 'continuum of care' for the patients. Finally, the advent of genomic analysis has generated new possibilities for evaluating off-label targeted therapies in refractory cancers and for enrolment in clinical trial with matched targeted therapeutics. Above all, physicians should personalise the treatment, considering several factors, including molecular profile, tumour location, achievable goals, patient characteristics and preference.
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